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Whole-brain patterns of 1H-magnetic resonance spectroscopy
imaging in Alzheimer's disease and dementia with Lewy bodies
L Su1, AM Blamire2, R Watson3, J He4, L Hayes1 and JT O’Brien1
Magnetic resonance spectroscopy has demonstrated metabolite changes in neurodegenerative disorders such as Alzheimer’s
disease (AD) and dementia with Lewy bodies (DLB); however, their pattern and relationship to clinical symptoms is unclear. To
determine whether the spatial patterns of brain-metabolite changes in AD and DLB are regional or diffused, and to examine
whether the key metabolite levels are associated with cognitive and non-cognitive symptoms, we acquired whole-brain spatially
resolved 3T magnetic resonance spectroscopic imaging (MRSI) data from subjects with AD (N= 36), DLB (N= 35) and similarly aged
controls (N= 35). Voxel-wise measurement of N-acetylaspartate to creatine (NAA/Cr), choline to Cr (Cho/Cr), myo-inositol to Cr
(mI/Cr) as well as glutamate and glutamine to Cr (Glx/Cr) ratios were determined using MRSI. Compared with controls, AD and DLB
groups showed a signiﬁcant decrease in most brain metabolites, with NAA/Cr, Cho/Cr and mI/Cr levels being reduced in posterior
cingulate, thalamus, frontotemporal areas and basal ganglia. The Glx/Cr level was more widely decreased in DLB (posterior
cingulate, hippocampus, temporal regions and caudate) than in AD (only in posterior cingulate). DLB was also associated with
increased levels of Cho/Cr, NAA/Cr and mI/Cr in occipital regions. Changes in metabolism in the brain were correlated with
cognitive and non-cognitive symptoms in the DLB but not in the AD group. The different patterns between AD and DLB may have
implications for improving diagnosis, better understanding disease-speciﬁc neurobiology and targeting therapeutics. In addition,
the study raised important questions about the role of occipital neuroinﬂammation and glial activation as well as the glutamatergic
treatment in DLB.
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INTRODUCTION
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are
the two commonest subtypes of degenerative dementia in older
people.1 They share common clinical and neuropsychological
features. In DLB, there appears to be an interruption of awareness,
which is often associated with transient episodes of confusion and
communication difﬁculties. Remission to near-normal cognitive
function can occur spontaneously in the absence of clear
environmental triggers. In addition to such cognitive ﬂuctuation,
visual hallucinations, which are false perceptions in the absence of
an external stimulus that are accompanied by a compelling sense
of reality, and motor Parkinsonism are also the core clinical
features of DLB. In addition, subjects with DLB show poor
executive function, attention and visual processing.2,3 Not only
basic processing speed but also high-level attention functions,
such as selective attention and the sustained attention, are
impaired in DLB.4 These attentional deﬁcits have an important role
in other symptoms of DLB such as visual hallucinations.5
Several biophysical systems have been tested in DLB. A putative
candidate system is the basal–forebrain cholinergic system, which
has widespread projections to the neocortex. In DLB, it is well
established that there is a marked loss of basal–forebrain
cholinergic neurons compared with AD;6 furthermore, abnormality
of nicotinic receptor binding in DLB patients appears to be
associated with disturbances of consciousness.7,8 Pharmacological
evidence has demonstrated that anticholinergic drugs can induce
a symptom proﬁle of altered consciousness that is similar to
cognitive ﬂuctuation in DLB.9 Conversely, cholinesterase inhibitors
signiﬁcantly improve the cognitive ﬂuctuation in DLB.9 Cortical
systems responsible for arousal and attention may be also affected
in DLB, therefore contributing to the development of cognitive
ﬂuctuation, for example, dopamine and noradrenergic systems as
well as hypothalamus and midbrain that mediate arousal and
circadian function.10,11
DLB can be characterised by the presence within neurons of
Lewy bodies, containing misfolded α-synuclein protein; however,
in comparison with AD, it has less severe brain atrophy, instead
with a more diffuse and less focal pattern,12,13 and relatively
preserved medial temporal lobes.14–16 In addition, β-amyloid
plaques and tau neuroﬁbrillary tangles (that is, AD-like patholo-
gies) are also found in DLB. While lacking regional-speciﬁc
structural changes, studies of brain metabolism and neurotrans-
mitter systems using metabolic 18-ﬂuoro-deoxyglucose positron
emission tomography and perfusion single-photon emission
computed tomography have highlighted the involvement of
occipital,17–19 temporoparietal20 and subcortical areas21–23 in DLB.
There is also evidence in AD that such functional imaging changes
can be detected many years before structural atrophy and the
onset of clinical symptoms.24 Thus, studying patterns of brain
biochemical changes in AD and DLB can provide important
information for diagnosis and treatments as well as for under-
standing disease-speciﬁc neurobiology.
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In vivo assessment of metabolite levels using 1H-magnetic
resonance spectroscopy has provided a substantial amount of
evidence on biochemical abnormalities in AD and DLB.25 It has
been reported that the N-acetylaspartate (NAA) level was lower in
patients with AD in posterior cingulate, frontal, temporal and
parietal lobes.26–28 NAA has frequently been seen as a neuronal
marker, and was also found to be decreased in several other
dementia types, such as DLB.29,30 Regarded as a glia marker,
myo-inositol (mI) was found to be elevated in AD16,17 and DLB.31
Reduction in glutamate and glutamine (Glx) has also been found
in AD32 and DLB.33 Thus, the literature supports the potential
utility of MR spectroscopy to assist ante-mortem detection for AD
and DLB.
However, the majority of previous studies have either focused
on a single voxel, often not in an area known to be affected by
pathology, or included only a very small number of brain regions.
This approach is limited in its ability to provide full information
about whether changes in AD and DLB are regional or diffused as
dysfunction outside these areas cannot be assessed. The literature
on MRS in AD and DLB has provided quite disparate results,16
which is likely due, at least in part, to differences in the location of
targeted brain regions. Finally, because of the low signal-to-noise
ratio in MRS, the reported effect size in most previous studies
was relatively small, making it very sensitive to the selection of
brain regions. Hence, there is a pressing need to provide unbiased
and robust voxel-wise whole-brain estimates for MRS data in
dementia.
Here, we used a 1H-magnetic resonance spectroscopic imaging
(MRSI) method to overcome the above-mentioned limitations in
previous research in order to investigate the spatial pattern of
MRSI in AD, DLB and similarly aged control groups. We also
assessed the relationship between MRS changes and clinical and
cognitive measurements in subjects with AD and DLB.
MATERIALS AND METHODS
Subject recruitment and assessment
The study was performed on 106 subjects in three groups (AD, DLB and
cognitively normal controls). Thirty-six individuals with probable AD and
thirty-ﬁve people with probable DLB were recruited from referrals to
secondary care old-age psychiatry and neurology services.34 Thirty-ﬁve
controls were recruited from among spouses and friends of the subjects
with dementia or from advertisements in local community newsletters. The
sample size was selected after a power calculation based on prior
literature. For example, Kantarci et al.25 investigated MRS changes in AD
and MCI as well as controls at 1.5 T using single-voxel methods. The mean
(s.d.) NAA to creatine (Cr) ratios were 1.53 (0.11) in controls (N= 85), 1.49
(0.09) in MCI (N=49) and 1.43 (0.1) in AD (N=60), a reduction of 1 s.d.
between AD and controls. Thus, a sample size of N=35 in each group gives
a power of over 90% to detect a similar magnitude of difference between
groups with alpha= 0.05 in the current study. All participants underwent
clinical and neuropsychological evaluations with diagnostic procedures
previously employed by our group.24
Assessment of global cognitive function in all participants involved use
of the Cambridge Cognitive Examination (CAMCOG), which incorporates
the Mini-Mental State Examination (MMSE).35 Motor Parkinsonism was
assessed with the Uniﬁed Parkinson’s Disease Rating Scale III (UPDRS).36
For subjects with DLB, cognitive ﬂuctuation was evaluated with the
Clinician Assessment of Fluctuation Scale.37 The research was approved by
the local ethics committee. All participants (or carers if subjects lacked
capacity) provided written informed consent/assent.
MRI/MRSI data acquisition
Participants underwent magnetic resonance imaging (MRI) scanning on a
3T Philips Achieva MRI system (Intera Achieva scanner, Philips Medical
Systems, Eindhoven, Netherlands) with an eight-channel receiver head coil.
Structural images were acquired using a T1-weighted volumetric sequence
(3D MPRAGE, sagittal acquisition aligned with the AC-PC line, 1 mm
isotropic resolution, matrix 240× 240× 180, TR = 9.6 ms, TE = 4.6 ms, ﬂip
angle = 8°, SENSE factor = 2). MR spectroscopy images were acquired using
a multislice, single-spin echo, spectroscopic imaging sequence, incorpor-
ating octagonal spatial presaturation bands placed over the skull/scalp to
minimise lipid contamination (10 × 10 mm in-plane resolution, ﬁve 18 mm
slices, matrix 24 × 20 × 5, TR = 3450 ms, TE = 35 ms). The pack of MRSI slices
was angulated along the AC-PC line and covered 90 mm of brain tissue in
the superior–inferior direction (Figure 1). Two subjects with AD and one
control did not complete the imaging protocol and so were excluded.
Statistical tests of demographic, clinical and cognitive measures
Group characteristics were evaluated with Statistical Toolbox of Matlab
(www.mathworks.co.uk/products/statistics). Differences in demographic
and clinical data were assessed with use of either t-tests for continuous
variables or χ2-tests for categorical measures. For each test statistic, a
probability value of Po0.05 was regarded as signiﬁcant.
Mass spectral analysis
Within each voxel of MRSI, we analysed the spectra using jMRUI v.4 (http://
www.mrui.uab.es/mrui/) to quantify the level of NAA, Cho, mI, Glx and
creatine (Cr). Residual water was removed using an SVD ﬁlter with 20
components,38 and the initial spectral zero-order phasing was manually
adjusted across all voxels. Then, we used the QUEST algorithm39 to
quantify each metabolite based on a predeﬁned metabolite database,
which captured the spectral proﬁles of these metabolites in vitro. During
ﬁtting, zero-order phase variation was constrained to be ± 45 Hz of the
initial estimate. The results of QUEST analysis were a set of estimated levels
for all ﬁve metabolites in each voxel for each subject. Instead of analysing a
small number of spectral for each subject, we performed a mass analysis
for all 2400 voxels within a single subject scan and for all 104 subjects.
MRI segmentation and normalisation
Volumetric structural MRI (T1-weighted) images were ﬁrst segmented
using Gaussian mixture model implemented in the VBM toolbox, and brain
tissues were classiﬁed into grey matter (GM), white matter (WM) and
cerebrospinal ﬂuid. GM probability maps were nonlinearly normalised to
standard MNI space (www.mni.mcgill.ca) using the diffeomorphic registra-
tion algorithm (DARTEL) in SPM v.8.40
MRSI and MRI co-registration
MRS images have a lower resolution (10 × 10 × 18 mm) than the structural
T1 images (1 × 1× 1 mm); therefore, linear interpolation was applied to
MRSI data before co-registering them to the MRI data using a modiﬁed
Gannet v.2 function (gabamrs.blogspot.co.uk). Owing to the lack of
anatomical information in the MRSI data, conventional registration
methods (for example, mutual information approach) are not applicable.
Instead, the Gannet-based approach assumes that the MRSI and
accompanying structural scan are in good registration and uses the image
header information (image origin coordinates, angulation and voxel size)
to match MRSI and MRI data. The quality of co-registration was validated
by visual inspection for any motion-related mis-co-registration. That is, we
overlaid the averaged MRS maps of all metabolites including a map of lipid
signal on the anatomical MRI from the same subject and visually checked
whether the key anatomical landmarks (lateral ventricles and scalp) are
registered correctly because cerebrospinal ﬂuid has a low level of
metabolism and the scalp has a high level of lipid signal.
MRS image normalisation and smoothing
After co-registeration, we masked MRS maps of GM and WM by tissue
probability maps derived from T1-weighted MRI images in each
participant’s native space in order to remove non-brain areas (c.f.
Figure 1). We then transformed the masked MRS maps into the standard
MNI space using the participant-speciﬁc diffeomorphic parameters
estimated from the previous DARTEL procedure. However, we did not
apply modulation in order to avoid confound of age and disease-related
brain volume changes, and preserve the original biochemical concentra-
tion in the patients' space. We then computed the images of the ratios
between the metabolites of interest (NAA, Cho, mI and Glx) and the
internal reference (Cr). In order to reduce the noise level, we further
smoothed the MRS maps with an isotropic Gaussian kernel of 8 mm full-
width at half-maximum.
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Considerations for partial volume effect
The use of ratio between brain metabolite and the internal reference is
common in most MRS studies in the literature. Here, it corrected for the
spatial variation in the sensitivity proﬁle of the head coil but also, more
importantly for the potential partial volume effect caused by non-brain
tissue. Speciﬁcally, in areas of atrophy, which are expected in these patient
groups, tissue loss may reduce the levels of all metabolites, but particularly
Cr, which is ubiquitous to all cells and hence take the ratio to Cr, should
ameliorate this potential confound of partial volume.
Whole-brain voxel-wise analysis
In order to explore disease-related differences in the metabolic proﬁle in
AD, DLB and control subjects, we used the General Linear Model with age
and gender as covariates, and then performed ‘omnibus’ tests of 3
groups × 4 metabolites factorial analysis of variance (ANOVA) for the main
effect of groups in GM and WM separately. The investigators were blinded
to the clinical diagnosis before this stage of the analysis. The false-positive
rate was controlled using the standard family-wise error correction for
multiple comparisons implemented in SPM statistical package, and was
thresholded at Po0.05 at the cluster level.
Post hoc regional analysis
On the basis of the whole-brain analysis, we extracted the averaged
metabolite signal levels from signiﬁcant clusters. Post hoc t-tests were
performed in order to explore which metabolite or group was driving the
results in the whole-brain ANOVA. We also correlated the averaged signal
from each cluster with cognitive and clinical measures including the
CAMCOG, UPDRS, MMSE and Clinician Assessment of Fluctuation scale. The
post hoc analysis was uncorrected for multiple comparisons because it was
based on the whole-brain family-wise error-corrected clusters.
RESULTS
Demographic, clinical and cognitive measures
There were no signiﬁcant differences among AD, DLB and control
groups for age, sex and education (Table 1). On all cognitive and
clinical measures, AD and DLB subjects scored less well than
controls (statistics not shown) as we have reported previously in
this speciﬁc patient cohort.41,42 As expected, subjects with DLB
scored signiﬁcantly higher in UPDRS and cognitive ﬂuctuation
scale than AD; however, they did not differ in MMSE and CAMCOG
scores.
Whole-brain ANOVA for the main effect of groups
We found a signiﬁcant main effect of group in the GM of the
occipital cortex, posterior cingulate, prefrontal cortex, anterior
hippocampus (extending to parahippocampus and amygdala),
posterior hippocampus, superior temporal areas, putamen,
caudate and thalamus across all metabolites (Figure 2). In the
WM, we found a signiﬁcant cluster in the corpus callosum. (See
Supplementary Information for additional group analysis of each
metabolite.)
Table 1. Demographics, clinical and neuropsychological measures
Controls DLB AD Statistics
N 34 35 35 —
Gender (m:f ) 20:14 27:8 20:15 0.12
Age (years) 76.8 (5.2) 78.4 (6.9) 78.3 (5.8) 0.94
Education (years) 11.6 (2.5) 10.8 (2.6) 11.0 (3.4) 0.06
UPDRS 1.9 (1.9) 26.0 (10.7) 5.6 (4.4) o0.001
CogFluct — 6.1 (3.8) 2.0 (3.6) o0.001
MMSE 29.1 (1.0) 20.3 (5.3) 19.3 (4.3) 0.39
CAMCOG 97.3 (3.8) 67.7 (15.2) 65.3 (11.8) 0.46
Abbreviations: AD, Alzheimer’s disease; CAMCOG, Cambridge Cognitive
Examination; DLB, dementia with Lewy bodies; f, female; m, male; MMSE,
Mini-Mental State Examination; UPDRS, Uniﬁed Parkinson’s Disease Rating
Scale III. Values expressed as mean (s.d.).
Figure 1. Whole-brain MRS analysis. Each spectral was analysed to extract concentrations of ﬁve major metabolites (Cr, Cho, Glx, NAA and mI),
which were then converted into 3D maps in subjects’ native space. A modiﬁed SPM procedure was applied to remove non-brain areas from
the metabolism maps and normalise to the standard MNI space using high-resolution T1-weighted MRI data. The ratio between other
metabolites and the internal reference Cr was computed before the maps were smoothed for statistical analysis. 3D, 3 dimensional; Cho,
choline; Cr, creatine; Glx, glutamate and glutamine; GM, grey matter; mI, myo-inositol; MRI, magnetic resonance imaging; MRS, magnetic
resonance spectroscopy; NAA, N-acetylaspartate; WM, white matter.
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Post hoc analysis within signiﬁcant clusters
In the post hoc analysis, we focused on main clusters derived from
the whole-brain ANOVA showing that the main effect of group
was mainly driven by reductions of metabolites in AD and DLB
relative to their controls (Figure 3).
Subjects with AD and DLB had a signiﬁcantly reduced Cho/Cr
level in the posterior cingulate, thalamus, superior temporal areas,
prefrontal cortex and caudate (Figure 3). However, the occipital
Cho/Cr level was signiﬁcantly greater in DLB than in AD. Decreases
in NAA/Cr were found in the posterior cingulate, thalamus,
superior temporal regions, prefrontal cortex and caudate in AD
and DLB. However, subjects with AD had signiﬁcantly lower NAA/
Cr levels in the temporal and occipital cortex than DLB. In AD and
DLB, the mI/Cr level was reduced in the posterior cingulate,
hippocampus, superior temporal lobes and caudate. In AD, the mI/
Cr level was also lower than controls in the prefrontal cortex,
whereas in DLB it was greater than controls in the occipital cortex.
Subjects with DLB showed a reduction in the Glx/Cr level in the
posterior cingulate, hippocampus, temporal cortex and caudate.
However, we only found a signiﬁcant decrease in Glx/Cr in the
posterior cingulate in AD, but not in other regions. Finally, in the
corpus callosum, we found a reduced Cho/Cr and NAA/Cr levels in
AD and a reduced NAA/Cr in DLB.
Correlation between cognitive/clinical measures and MRSI
Figure 4 shows that the mI/Cr level was signiﬁcantly correlated
with the CAMCOG score in the temporal cortex in DLB. In the
prefrontal cortex, the Cho/Cr was signiﬁcantly inversely correlated
with the UPDRS score in DLB. Finally, the NAA/Cr level in the
hippocampus was signiﬁcantly inversely correlated with the
clinician ﬂuctuation scale. We found no signiﬁcant correlations
between MRS data and cognitive/clinical measurements in AD.
DISCUSSION
Using a novel approach, we investigated whole-brain patterns of
brain metabolites using 1H-proton MRS in AD and DLB, the two
commonest neurodegenerative dementias in older people. Our
results showed areas of the brain, in which there were maximum
variation in metabolites among the groups in a whole-brain
ANOVA. These brain areas involve both cortical and subcortical
structures, and in regions where AD and DLB pathology are
commonly found.43 A cluster occupying middle and posterior
cingulate was signiﬁcant in distinguishing the patient groups
from controls in most metabolites studied here, partly support-
ing ﬁndings in the prior literature.15 Although both groups
showed a pattern of reduction in NAA/Cr, Cho/Cr and mI/Cr
levels, the Glx/Cr level was more widely disrupted in DLB
than in AD. Our results also suggest that the occipital region is
one of the key structures that signiﬁcantly differentiated the AD
and DLB groups. Next, we will discuss ﬁndings on each metabolite
in turn.
The Cho/Cr level
In MRS, the Cho signal is mainly because of cytosolic glyceropho-
sphocholine and phosphocholine found in myelin and the cell
membrane. Therefore, variation in the Cho signal implies changes
in WM integrity and membrane turnover.44,45 Although previous
studies showed mixed and inconsistent results,16 we found a
general reduction in the Cho/Cr level but an increase in occipital
regions in DLB. The increase in the occipital Cho/Cr level in DLB
compared with AD is a different pattern from the overall reduction
of Cho/Cr in the rest of regions of interest. It is possible that
membrane (phospholipids) turnover was higher in this brain region
in DLB, consistent with previous single-photon emission computed
tomography studies showing occipital involvement in DLB7 and the
visual spatial impairments in DLB. However, it has also been
reported that the occipital Cr level might be lower in DLB compared
with AD.18 This can also result in a higher Cho/Cr ratio. Finally, the
Cho/Cr level in the corpus callosum was reduced in AD.
In addition, a reduction in prefrontal Cho/Cr level was correlated
with more severe Parkinsonism, that is, the total UPDRS ratings, in
DLB. Although it is well known that prefrontal dopamine deﬁcits
in Parkinson’s disease is strongly related to motor symptoms,
Figure 2. Magnetic resonance spectroscopic imaging (MRSI) statistical parameter (F ratio) maps from whole-brain ANOVA for the main effect
of groups. Signiﬁcant clusters FWE, Po0.05) shown in yellow/red are located in both cortical (prefrontal, temporal and cingulate) and
subcortical (CAD, PUM and THM) areas. For display purposes, the GM and WM results are shown in different views (axial, GM and sagittal, WM).
ANOVA, analysis of variance; CAD, caudate; CC, corpus callosum; FWE, family-wise error; GM, grey matter; HIP, hippocampus, parahippocampus
and amygdala; OCC, occipital cortex; PCC, posterior cingulate cortex; PFC, prefrontal cortex; PUM, putamen; STG, superior temporal cortex;
THM, thalamus; WM, white matter.
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and non-dopamine systems mainly contribute to cognitive
symptoms,9 our data showed that cholinergic activity maybe
another predictor for motor symptoms in DLB. This ﬁnding also
points out the potential interaction between dopaminergic and
cholinergic circuitries in prefrontal areas in Lewy body diseases.
The NAA/Cr level
NAA is mainly located in the bodies, axons and dendrites of
neurons; therefore, it has been regarded as a marker of neuronal
number, density and viability as well as mitochondrial function.15
A reduction in the NAA/Cr level has been consistently reported in
Figure 3. Post hoc analyses of signiﬁcant Anchor clusters from SPM: (a) Cho/Cr ratio, (b) NAA/Cr ratio, (c) mI/Cr ratio and (d) Glx/Cr ratio. Horizontal
lines represent signiﬁcant difference (Po0.05 uncorrected) between two groups: red, AD versus controls; blue, DLB versus controls; and
green, DLB versus AD. Error bars are s.e.m. *Po0.05, **Po0.01 and ***Po0.001. AD, Alzheimer’s disease; CAD, caudate; CC, corpus callosum;
DLB, dementia with Lewy bodies; HC, controls; HIP, hippocampus, parahippocampus and amygdala; OCC, occipital cortex; PCC, posterior
cingulate cortex; PFC, prefrontal cortex; STG, superior temporal cortex; THM, thalamus.
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neurodegeneration.16 Here, we also showed a widespread reduc-
tion of the NAA/Cr level in both AD and DLB groups, implicating
impairments in neuronal integrity and/or neuronal loss.
In superior temporal and occipital areas, there was a
signiﬁcantly lower NAA/Cr in AD than in DLB, suggesting a more
extensive loss of neuronal function in AD. The corpus callosum
NAA/Cr level was lower in AD and DLB; however, we did not ﬁnd a
signiﬁcant reduction in the NAA/Cr level in hippocampus, a brain
structure that is ﬁrst and substantially affected by AD pathology in
the same cohort31 and in other studies. However, in the DLB
group, the level of hippocampal NAA/Cr signiﬁcantly correlated
with the severity of cognitive ﬂuctuation, that is, a lower level of
NAA/Cr was linked to higher degree of ﬂuctuation. A very wide
range of brain systems has been implicated in cognitive
ﬂuctuation,46 including attention and default mode network,
and hippocampus function is closely coupled with default mode
network (for example, posterior cingulate) during task and rest.47
The mI/Cr level
mI is present in glial cells, and thus has been frequently associated
with inﬂammation or gliosis in the brain. Unlike previous studies,16
we found an overall decrease of mI/Cr in AD and DLB, implying a
possible lower rather than greater extent of glial cell activation in
the majority of brain areas. However, the DLB group showed a
higher occipital mI/Cr level. In addition, temporal mI/Cr was
correlated with cognitive performance (CAMCOG) in the DLB
group, reﬂecting a potential modulatory effect immune reaction in
dementia.
Here, in posterior cingulate, superior temporal lobe, hippocam-
pus and basal ganglia structures, we not only saw a reduction in
NAA/Cr, Cho/Cr and Glx/Cr, suggesting a decrease in neuronal
density and integrity as well as energy metabolism, but also a
decrease in glial activation and inﬂammation reaction. One
explanation for our ﬁndings is that the inﬂammation may occur
in very early stages of pathology, and, as the disease progresses,
this process may become exhausted because of possible glial cell
loss. Our cohort, although relatively mild from a clinical viewpoint,
could be seen as reasonably advanced in terms of their disease
progression as all had a clinical diagnosis of dementia. This, as well
as occipital increases of mI/Cr in DLB, which may reﬂect a
heightened inﬂammatory response there, needs further investiga-
tion. Finally, in the occipital region, which is more affected in DLB
than in AD, we found increases in both NAA/Cr and Cho/Cr levels,
implying a possible compensatory mechanism coexisting with the
raised brain immune systems.
The Glx/Cr level
Glutamate and glutamine metabolism is related to both neurons
and glial cells. Separation of signals from glutamate from
glutamine is challenging, and so both metabolites are commonly
considered together. Reduction in the Glx/Cr level may also imply
dysfunction and loss of glutamatergic neurons.23 Consistent with
previous ﬁndings, we showed a widespread decrease in Glx/Cr
ratio in DLB, and only in posterior cingulate in AD, suggesting that
the widespread Glx/Cr deﬁcit is a distinctive feature in DLB. Of
interest, memantine, an N-methyl-D-aspartate antagonist, has
been reported to show efﬁcacy in DLB and AD.48 Should our
results have wider conﬁrmation, this would support the further
development and testing of glutamatergic therapies in DLB.
Comparison with previous studies and design considerations
When compared with GM atrophy,31 diffusion tensor imaging (DTI)
abnormalities32 and relaxometry changes24 in the same cohort, we
found that the spatial distribution of metabolic dysfunction is more
similar to relaxometry and DTI changes than atrophy. In particular,
we found signiﬁcant metabolic changes in subcortical regions,
which showed a relative structural preservation in DLB, implicating
that MRS and DTI maybe more sensitive in detecting changes in
neuronal and glial integrity before there is cell loss.49
Our study has advanced from most previous MRS investigations
in neurodegenerative diseases, which have only focused on a
single or limited number of brain areas, such as posterior
cingulate. A signiﬁcant drawback of such single voxel (or a small
number of voxels) approach is selection bias, that is, a tendency for
new studies to base their hypothesis on existing data and select
regions of interest that have already been tested and the null
hypothesis rejected. This approach tends to ﬁnd positive results
conﬁrming the prior research but suffers from the risk of a higher
type I error rate. A related problem is publication bias,50 which
favours positive ﬁndings over negative ones, thus inﬂating the real
effect size. Therefore, limitations of previous hypothesis-driven
methods are as follows: (1) the majority of the brain areas are
underexplored and (2) the effect size can be overestimated. For
diseases with diffuse patterns of pathology, such as DLB, the
previous single-voxel approach is arguably suboptimal. Finally, it is
difﬁcult to compare across studies that have different selections of
brain region.
In our study, the design and analysis were based on classic
statistical analysis because our work was looking for disease-
related differences in metabolic proﬁle in AD and DLB. An
alternative analysis would be to use the data to perform
classiﬁcation between subject groups using methods such as
Figure 4. Correlational Anchor analysis with: (a) cognition (CAMCOG), (b) motor symptoms (UPDRS) and (c) cognitive ﬂuctuation. Signiﬁcant
correlation between metabolism and cognitive/clinical measurements (Po0.05, uncorrected) in DLB. Averaged levels of different metabolites
were extracted from the corresponding signiﬁcant clusters in the SPM analysis. DLB, dementia with Lewy bodies.
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support vector machine. The emerging machine-learning methods
have been used for differentiating AD, MCI and other types of
dementia.51 Although majority of the imaging studies employed
group-level analysis, support vector machine and similar classiﬁca-
tion techniques can potentially have higher sensitivity and
speciﬁcity for diagnosis at an individual subject level.52 The spatial
information about metabolic proﬁle is important to understand the
disease-speciﬁc neurobiology and relate it to known pathology in
these conditions. Therefore, recent development in multivariate
analysis of neuroimaging data has advanced from classifying
whole-brain pattern to localising regional effects. For example, the
‘searchlight’ algorithm, developed by Kriegeskorte and co-
workers53,54 for MRI and Su et al.55 for MEG, allows support vector
machine to use regional multivariate pattern information and
remain spatially resolved. Thus, future studies, especially those with
small sample size or intended for individual-level discrimination,
should consider advanced multivariate pattern analyses.
CONCLUSION
In summary, our ﬁndings on major brain metabolite changes and
their correlations with cognitive and non-cognitive symptoms are
broadly in agreement with previous research. However, the study
used an unbiased whole-brain voxel-wise approach. Our results
also raised important questions about the role of occipital
neuroinﬂammation and glial activation as well as the glutamater-
gic treatment in DLB.
The current study has some limitations. For example, the mass
spectral analysis was semi-automatic. In addition, we computed
the ratios between metabolites rather than the absolute
concentration of metabolites. This approach is sensitive to
potential changes in Cr levels, and also makes the interpretation
of the results more difﬁcult. Future research should avoid
referencing to the Cr level, although the use of such ratio data
can naturally address the partial volume effect, which is often
caused by severe atrophy in our cohort, without using explicit
partial volume correction methods.
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